{"title":"Catatonia Associated with Buprenorphine-Induced Toxic Leukoencephalopathy","authors":"Danielle DeCicco, MD, PhD, Jessica Thayer, MD, Ziad Dimachkie, MD","doi":"10.21885/wvmj.2022.22","DOIUrl":null,"url":null,"abstract":"It is well-known that West Virginia (WV) is one of the states most affected by the opioid epidemic. Recently, WV has implemented a program to expand buprenorphine use as part of a multi-prong approach to treat opioid use disorder accompanied by positive outcomes. However, buprenorphine can be diverted and obtained outside of a medical provider's guidance. Given the prevalence of buprenorphine use in WV, we aim to present original clinical data prompting clinicians to recognize buprenorphine as a potential cause of toxic leukoencephalopathy. We describe the case of a 28-year-old female who presented with catatonia believed to be secondary to buprenorphine, and we discuss the diagnostic challenges and therapeutic management of buprenorphine-induced toxic leukoencephalopathy.","PeriodicalId":23032,"journal":{"name":"The West Virginia medical journal","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The West Virginia medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21885/wvmj.2022.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
It is well-known that West Virginia (WV) is one of the states most affected by the opioid epidemic. Recently, WV has implemented a program to expand buprenorphine use as part of a multi-prong approach to treat opioid use disorder accompanied by positive outcomes. However, buprenorphine can be diverted and obtained outside of a medical provider's guidance. Given the prevalence of buprenorphine use in WV, we aim to present original clinical data prompting clinicians to recognize buprenorphine as a potential cause of toxic leukoencephalopathy. We describe the case of a 28-year-old female who presented with catatonia believed to be secondary to buprenorphine, and we discuss the diagnostic challenges and therapeutic management of buprenorphine-induced toxic leukoencephalopathy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
